<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00573417</url>
  </required_header>
  <id_info>
    <org_study_id>34-02</org_study_id>
    <secondary_id>Cephalon 670 Study</secondary_id>
    <nct_id>NCT00573417</nct_id>
  </id_info>
  <brief_title>A Placebo-Controlled Trial of Modafinil (Provigil) Added to Clozapine in Patients With Schizophrenia</brief_title>
  <official_title>A Placebo-Controlled Trial of Modafinil (Provigil) Added to Clozapine in Patients With Schizophrenia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>North Suffolk Mental Health Association</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Cephalon</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>North Suffolk Mental Health Association</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This pilot study is an eight-week, randomized, double-blind, placebo-controlled, escalating
      dose trial of the novel vigilance-promoting drug, modafinil, added to a stable dose of
      clozapine in 40 patients with schizophrenia or schizoaffective disorder. Modafinil will be
      initiated at 100 mg/d. After 2 weeks, the study drug may be increased to 200 mg/d and after 4
      weeks, study drug may be increased to a maximum of 300 mg/d. Dose escalation will be based
      upon persistence of sedation versus emergence of side effects.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This pilot study is an eight-week, randomized, double-blind, placebo-controlled, escalating
      dose trial of the novel vigilance-promoting drug, modafinil, added to a stable dose of
      clozapine in 40 patients with schizophrenia or schizoaffective disorder. Modafinil will be
      initiated at 100 mg/d. After 2 weeks, the study drug may be increased to 200 mg/d and after 4
      weeks, study drug may be increased to a maximum of 300 mg/d. Dose escalation will be based
      upon persistence of sedation versus emergence of side effects.

        1. Evaluate tolerability and safety of modafinil compared to placebo using the SAFTEE and
           vital signs.

        2. Evaluate the effect size of modafinil compared to placebo upon wakefulness and fatigue
           using the Epworth Sleepiness Scale (ESS) and the Fatigue Severity Scale (FSS).

        3. Evaluate the effect size of modafinil compared to placebo upon negative symptoms using
           the SANS total score.

        4. Evaluate the effect size of modafinil compared to placebo upon cognitive functioning
           using a standard battery of cognitive tests.

        5. Evaluate the effect size of modafinil compared to placebo upon weight, BMI, waist/hip
           circumference and fasting glucose and lipids.

        6. Effect the variability of response in placebo and modafinil groups for each of the
           outcome measures.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2003</start_date>
  <completion_date type="Actual">November 2007</completion_date>
  <primary_completion_date type="Actual">November 2007</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluate the effect size of modafinil compared to placebo upon cognitive functioning using a standard battery of cognitive tests.</measure>
    <time_frame>8 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluate tolerability and safety of modafinil compared to placebo using the SAFTEE and vital signs.</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the effect size of modafinil compared to placebo upon wakefulness and fatigue using the Epworth Sleepiness Scale (ESS) and the Fatigue Severity Scale (FSS).</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the effect size of modafinil compared to placebo upon negative symptoms using the SANS total score.</measure>
    <time_frame>8 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the effect size of modafinil compared to placebo upon weight, BMI, waist/hip circumference and fasting glucose and lipids.</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect the variability of response in placebo and modafinil groups for each of the outcome measures.</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Schizophrenia</condition>
  <arm_group>
    <arm_group_label>modafinil</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>modafinil 100mg, 200mg, or 300mg (dose escalation)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>modafinil</intervention_name>
    <description>modafinil 100mg tablets. dose excalation up to 300mg</description>
    <arm_group_label>modafinil</arm_group_label>
    <other_name>Provigil</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of Schizophrenia, any subtype or schizoaffective disorder

          -  Ages 18-65 years

          -  Capable of providing informed consent, or capable of providing assent with a guardian
             who provides informed consent

          -  Stable dose of clozapine for at least 1 month

          -  Three months of stable psychotic symptoms

        Exclusion Criteria:

          -  Serious medical or neurological illness (unstable cardiac disease, seizure disorder,
             malignancy, liver or renal impairment, etc.)

          -  Current substance abuse

          -  Pregnancy, nursing, or unwilling to use appropriate birth control measures during
             participation if female and fertile.

          -  Unable to complete neuropsychological tests

          -  History of serious blood dyscrasia requiring discontinuation of clozapine

          -  Serious suicidal or homicidal risk within the past six months

          -  Current treatment with a psychostimulant
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Donald Goff, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massachusetts General Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Freedom Trail Clinic</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 13, 2007</study_first_submitted>
  <study_first_submitted_qc>December 13, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 14, 2007</study_first_posted>
  <last_update_submitted>August 11, 2009</last_update_submitted>
  <last_update_submitted_qc>August 11, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 12, 2009</last_update_posted>
  <responsible_party>
    <name_title>Donald Goff, MD</name_title>
    <organization>Massachusetts General Hospital</organization>
  </responsible_party>
  <keyword>Schizophrenia</keyword>
  <keyword>Clozapine</keyword>
  <keyword>Cognition</keyword>
  <keyword>Metabolic Syndrome</keyword>
  <keyword>Negative Symptoms</keyword>
  <keyword>Wakefulness</keyword>
  <keyword>Fatigue</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Schizophrenia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Modafinil</mesh_term>
    <mesh_term>Armodafinil</mesh_term>
    <mesh_term>Clozapine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

